Access Bio, Inc. (KOSDAQ:950130)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,210.00
-90.00 (-2.73%)
At close: Feb 27, 2026
Market Cap112.91B -41.1%
Revenue (ttm)54.67B -54.5%
Net Income-28.04B
EPS-767.87
Shares Out35.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume172,110
Average Volume144,372
Open3,280.00
Previous Close3,300.00
Day's Range3,130.00 - 3,340.00
52-Week Range3,130.00 - 7,360.00
Beta0.29
RSI31.20
Earnings DateMar 17, 2026

About Access Bio

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; a... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 2002
Employees 101
Stock Exchange KOSDAQ
Ticker Symbol 950130
Full Company Profile

Financial Performance

In 2024, Access Bio's revenue was 112.46 billion, a decrease of -67.74% compared to the previous year's 348.64 billion. Losses were -347.58 million, -89.05% less than in 2023.

Financial Statements